Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 144 articles:
HTML format
Text format



Single Articles


    October 2019
  1. YOON SY, Yoon JH, Min GJ, Park SS, et al
    Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2019 Oct 7. pii: 10.1038/s41409-019-0708.
    PubMed     Text format    


    September 2019
  2. BAZARBACHI AH, Al Hamed R, Labopin M, Afanasyev B, et al
    Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2019 Sep 27. pii: 10.1038/s41409-019-0702.
    PubMed     Text format     Abstract available


  3. DEBUREAUX PE, Labopin M, Mamez AC, Lapusan S, et al
    Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Sep 25. pii: 10.1038/s41409-019-0690.
    PubMed     Text format     Abstract available


  4. BASQUIERA AL, Berro M, Yantorno S, Castro M, et al
    Haploidentical transplant in adult patients with acute lymphoblastic leukemia in Argentina: a comparison with matched related and unrelated donors.
    Bone Marrow Transplant. 2019 Sep 24. pii: 10.1038/s41409-019-0687.
    PubMed     Text format     Abstract available


  5. TACHIBANA T, Ishizaki T, Takahashi S, Najima Y, et al
    Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis.
    Bone Marrow Transplant. 2019 Sep 19. pii: 10.1038/s41409-019-0689.
    PubMed     Text format    


  6. TOMORI S, Morishima S, Nishi Y, Nakachi S, et al
    Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0669.
    PubMed     Text format     Abstract available


  7. MA Y, Qu C, Dai H, Yin J, et al
    Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0677.
    PubMed     Text format    


  8. GATWOOD KS, Labopin M, Savani BN, Finke J, et al
    Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.
    Bone Marrow Transplant. 2019 Sep 16. pii: 10.1038/s41409-019-0673.
    PubMed     Text format     Abstract available


  9. SOLOMON SR, Solh M, Jackson KC, Zhang X, et al
    Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program.
    Bone Marrow Transplant. 2019 Sep 16. pii: 10.1038/s41409-019-0675.
    PubMed     Text format     Abstract available


  10. XU J, Zhao R, Yang L, Gong H, et al
    Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2019 Sep 5. pii: 10.1038/s41409-019-0666.
    PubMed     Text format    


  11. EL FAKIH R, Kotb A, Hashmi S, Chaudhri N, et al
    Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients.
    Bone Marrow Transplant. 2019 Sep 5. pii: 10.1038/s41409-019-0667.
    PubMed     Text format     Abstract available


  12. SHADMAN M, Maloney DG, Storer B, Sandmaier BM, et al
    Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
    Bone Marrow Transplant. 2019 Sep 3. pii: 10.1038/s41409-019-0660.
    PubMed     Text format     Abstract available


    August 2019
  13. WANG X, Hu Y, Liu X, Yu J, et al
    Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy.
    Bone Marrow Transplant. 2019 Aug 5. pii: 10.1038/s41409-019-0625.
    PubMed     Text format     Abstract available


  14. PIERINI A, Ruggeri L, Carotti A, Falzetti F, et al
    The "ultimate" haploidentical transplantation for the elderly with high-risk acute myeloid leukemia.
    Bone Marrow Transplant. 2019;54.
    PubMed     Text format    


  15. SCHLEGEL P, Jung G, Lang AM, Doring M, et al
    ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL.
    Bone Marrow Transplant. 2019;54.
    PubMed     Text format     Abstract available


  16. EINSELE H, Rasche L, Topp MS, Martin Kortum K, et al
    The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.
    Bone Marrow Transplant. 2019;54.
    PubMed     Text format     Abstract available


  17. PIERINI A, Ruggeri L, Mancusi A, Carotti A, et al
    T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease.
    Bone Marrow Transplant. 2019;54.
    PubMed     Text format     Abstract available


  18. JACOBY E
    The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2019;54.
    PubMed     Text format     Abstract available


  19. NAGLER A, Ruggeri A
    Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT.
    Bone Marrow Transplant. 2019;54.
    PubMed     Text format     Abstract available


    June 2019
  20. MOUKALLED NM, Kharfan-Dabaja MA
    What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?
    Bone Marrow Transplant. 2019 Jun 3. pii: 10.1038/s41409-019-0584.
    PubMed     Text format     Abstract available


    May 2019
  21. YANO S, Yokoyama H, Yanada M, Mori J, et al
    Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
    Bone Marrow Transplant. 2019 May 31. pii: 10.1038/s41409-019-0571.
    PubMed     Text format     Abstract available


  22. RUGGERI A, Labopin M, Savani B, Paviglianiti A, et al
    Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.
    Bone Marrow Transplant. 2019 May 31. pii: 10.1038/s41409-019-0582.
    PubMed     Text format     Abstract available


  23. KANSAGRA AJ, Frey NV, Bar M, Laetsch TW, et al
    Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transp
    Bone Marrow Transplant. 2019 May 15. pii: 10.1038/s41409-019-0451.
    PubMed     Text format     Abstract available


  24. GUILLAUME T, Malard F, Magro L, Labopin M, et al
    Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0536.
    PubMed     Text format     Abstract available


  25. ALDOSS I, Nakamura R, Yang D, Salhotra A, et al
    Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0553.
    PubMed     Text format    


  26. YANADA M, Konuma T, Kuwatsuka Y, Kondo T, et al
    Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience.
    Bone Marrow Transplant. 2019 May 8. pii: 10.1038/s41409-019-0539.
    PubMed     Text format     Abstract available


    April 2019
  27. MASCHAN M, Shelikhova L, Ilushina M, Shekhovtsova Z, et al
    Outcome of alphabeta T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission.
    Bone Marrow Transplant. 2019 Apr 15. pii: 10.1038/s41409-019-0531.
    PubMed     Text format    


  28. YAMASAKI S, Aoki J, Mori J, Mizuno S, et al
    Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease.
    Bone Marrow Transplant. 2019 Apr 10. pii: 10.1038/s41409-019-0527.
    PubMed     Text format    


  29. LUBKING A, Dreimane A, Sandin F, Isaksson C, et al
    Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
    Bone Marrow Transplant. 2019 Apr 8. pii: 10.1038/s41409-019-0513.
    PubMed     Text format     Abstract available


    February 2019
  30. GODWIN CD, Fromm JR, Othus M, Sandmaier BM, et al
    Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.
    Bone Marrow Transplant. 2019 Feb 25. pii: 10.1038/s41409-019-0481.
    PubMed     Text format    


  31. OKAMOTO Y, Kudo K, Tabuchi K, Tomizawa D, et al
    Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0461.
    PubMed     Text format     Abstract available


  32. BATTIPAGLIA G, Boumendil A, Labopin M, Ciceri F, et al
    Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0459.
    PubMed     Text format     Abstract available


    January 2019
  33. DAHLBERG A, Leisenring W, Bleakley M, Meshinchi S, et al
    Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.
    Bone Marrow Transplant. 2019 Jan 22. pii: 10.1038/s41409-019-0438.
    PubMed     Text format     Abstract available


  34. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0446.
    PubMed     Text format     Abstract available


  35. WIKTOR-JEDRZEJCZAK W, Drozd-Sokolowska J, Eikema DJ, Hoek J, et al
    EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0448.
    PubMed     Text format     Abstract available


  36. HAMILTON BK, Rybicki L, Hirsch C, Przychodzen B, et al
    Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Bone Marrow Transplant. 2019 Jan 17. pii: 10.1038/s41409-019-0444.
    PubMed     Text format     Abstract available


  37. QU C, Li Z, Kang L, Wang Y, et al
    Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells.
    Bone Marrow Transplant. 2019 Jan 10. pii: 10.1038/s41409-018-0423.
    PubMed     Text format    


    December 2018
  38. YOSHIMITSU M, Utsunomiya A, Fuji S, Fujiwara H, et al
    A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Dec 13. pii: 10.1038/s41409-018-0400.
    PubMed     Text format     Abstract available


  39. ASSI R, Mahfouz R, Owen R, Gunthorpe M, et al
    PAX5, NOTCH3, CBFB, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia.
    Bone Marrow Transplant. 2018 Dec 10. pii: 10.1038/s41409-018-0419.
    PubMed     Text format    


  40. SUN W, Mo XD, Zhang XH, Xu LP, et al
    Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients.
    Bone Marrow Transplant. 2018 Dec 5. pii: 10.1038/s41409-018-0406.
    PubMed     Text format     Abstract available


  41. HU Y, Wang J, Wei G, Yu J, et al
    A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Dec 5. pii: 10.1038/s41409-018-0403.
    PubMed     Text format     Abstract available


    November 2018
  42. GRIMM J, Bill M, Jentzsch M, Beinicke S, et al
    Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.
    Bone Marrow Transplant. 2018 Nov 30. pii: 10.1038/s41409-018-0413.
    PubMed     Text format     Abstract available


  43. ALDOSS I, Pullarkat V
    Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?
    Bone Marrow Transplant. 2018 Nov 16. pii: 10.1038/s41409-018-0398.
    PubMed     Text format    


  44. GOWDA L, Shah M, Badar I, Bashir Q, et al
    Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.
    Bone Marrow Transplant. 2018 Nov 16. pii: 10.1038/s41409-018-0392.
    PubMed     Text format     Abstract available


  45. KIM HJ, Sohn HJ, Hong JA, Lee HJ, et al
    Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.
    Bone Marrow Transplant. 2018 Nov 8. pii: 10.1038/s41409-018-0383.
    PubMed     Text format    


  46. GIEBEL S, Marks DI, Boissel N, Baron F, et al
    Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute L
    Bone Marrow Transplant. 2018 Nov 1. pii: 10.1038/s41409-018-0373.
    PubMed     Text format     Abstract available


    October 2018
  47. ZHANG WP, Wang ZW, Hu XX, Chen J, et al
    Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
    Bone Marrow Transplant. 2018 Oct 19. pii: 10.1038/s41409-018-0356.
    PubMed     Text format     Abstract available


  48. MOUKALLED NM, El Darsa H, Haibe Y, Massoud R, et al
    Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation.
    Bone Marrow Transplant. 2018 Oct 4. pii: 10.1038/s41409-018-0347.
    PubMed     Text format    


  49. PINGEL J, Wang T, Hagenlocher Y, Hernandez-Frederick CJ, et al
    The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.
    Bone Marrow Transplant. 2018 Oct 2. pii: 10.1038/s41409-018-0345.
    PubMed     Text format     Abstract available


    September 2018
  50. KONGTIM P, Parmar S, Milton DR, Perez JMR, et al
    Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2018 Sep 26. pii: 10.1038/s41409-018-0344.
    PubMed     Text format     Abstract available


    August 2018
  51. KANELLOPOULOS A, Kaparou M, Xenou E, Paneesha S, et al
    Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
    Bone Marrow Transplant. 2018 Aug 16. pii: 10.1038/s41409-018-0297.
    PubMed     Text format     Abstract available


  52. YANADA M, Masuko M, Mori J, Aoki J, et al
    Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.
    Bone Marrow Transplant. 2018 Aug 14. pii: 10.1038/s41409-018-0301.
    PubMed     Text format     Abstract available


  53. DABAS R, Dharmani-Khan P, Modi M, Van Slyke T, et al
    Anti-thymocyte globulin's activity against acute myeloid leukemia stem cells.
    Bone Marrow Transplant. 2018 Aug 14. pii: 10.1038/s41409-018-0296.
    PubMed     Text format     Abstract available


  54. LEE CJ, Savani BN, Mohty M, Gorin NC, et al
    Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Tran
    Bone Marrow Transplant. 2018 Aug 13. pii: 10.1038/s41409-018-0286.
    PubMed     Text format     Abstract available


  55. SHETH V, Labopin M, Canaani J, Volin L, et al
    Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Bone Marrow Transplant. 2018 Aug 7. pii: 10.1038/s41409-018-0288.
    PubMed     Text format     Abstract available


    July 2018
  56. HIRANO M, Jimbo K, Ogawa M, Ochi K, et al
    Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2018 Jul 23. pii: 10.1038/s41409-018-0202.
    PubMed     Text format    


    June 2018
  57. TANG S, Shen H, Qu C, Dai H, et al
    Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Bone Marrow Transplant. 2018 Jun 25. pii: 10.1038/s41409-018-0249.
    PubMed     Text format     Abstract available


  58. GABELLI M, Zecca M, Messina C, Carraro E, et al
    Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0259.
    PubMed     Text format     Abstract available


  59. HOCHBERG J, Zahler S, Geyer MB, Chen N, et al
    The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leuke
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0247.
    PubMed     Text format     Abstract available


  60. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0248.
    PubMed     Text format    


  61. BONDA A, Punatar S, Gokarn A, Mohite A, et al
    Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
    Bone Marrow Transplant. 2018 Jun 8. pii: 10.1038/s41409-018-0222.
    PubMed     Text format    


    May 2018
  62. CRADDOCK C, Hoelzer D, Komanduri KV
    Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 May 31. pii: 10.1038/s41409-018-0203.
    PubMed     Text format     Abstract available


  63. KATO M, Kurata M, Kanda J, Kato K, et al
    Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0221.
    PubMed     Text format     Abstract available


  64. TKACZYK ER, Chen F, Wang J, Gandelman JS, et al
    Overcoming human disagreement assessing erythematous lesion severity on 3D photos of chronic graft-versus-host disease.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0211.
    PubMed     Text format    


  65. LINDEMANN M, Eiz-Vesper B, Steckel NK, Tischer S, et al
    Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor.
    Bone Marrow Transplant. 2018 May 8. pii: 10.1038/s41409-018-0209.
    PubMed     Text format    


  66. DREGER P, Michallet M, Bosman P, Dietrich S, et al
    Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone Marrow Transplant. 2018 May 4. pii: 10.1038/s41409-018-0207.
    PubMed     Text format     Abstract available


    April 2018
  67. YANG L, Tan Y, Shi J, Zhao Y, et al
    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2018 Apr 30. pii: 10.1038/s41409-018-0184.
    PubMed     Text format    


  68. BROWNBACK KR, Pitts LR, Abhyankar S
    Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Apr 26. pii: 10.1038/s41409-018-0182.
    PubMed     Text format    


  69. HALABURDA K, Labopin M, Houhou M, Niederwieser D, et al
    AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
    Bone Marrow Transplant. 2018 Apr 18. pii: 10.1038/s41409-018-0165.
    PubMed     Text format     Abstract available


  70. BATTIPAGLIA G, Ruggeri A, Labopin M, Volin L, et al
    Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Apr 16. pii: 10.1038/s41409-018-0169.
    PubMed     Text format     Abstract available


    March 2018
  71. BHATT VR, Chen B, Gyawali B, Lee SJ, et al
    Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Mar 27. pii: 10.1038/s41409-018-0164.
    PubMed     Text format     Abstract available


  72. CASTAGNOLA E, Bagnasco F, Menoni S, Muraca M, et al
    Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GIT
    Bone Marrow Transplant. 2018 Mar 21. pii: 10.1038/s41409-018-0160.
    PubMed     Text format    


  73. GAAFAR A, Sheereen A, Almohareb F, Eldali A, et al
    Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.
    Bone Marrow Transplant. 2018 Mar 16. pii: 10.1038/s41409-018-0123.
    PubMed     Text format     Abstract available


  74. GASSAS A, Sivaprakasam P, Cummins M, Breslin P, et al
    High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
    Bone Marrow Transplant. 2018 Mar 15. pii: 10.1038/s41409-018-0157.
    PubMed     Text format     Abstract available


  75. MARKEY KA, Gartlan KH, Kuns RD, Lane SW, et al
    Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT.
    Bone Marrow Transplant. 2018 Mar 13. pii: 10.1038/s41409-018-0148.
    PubMed     Text format    


  76. INOUE Y, Fuji S, Tanosaki R, Inamoto Y, et al
    Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.
    Bone Marrow Transplant. 2018 Mar 9. pii: 10.1038/s41409-018-0139.
    PubMed     Text format     Abstract available


  77. CHENG Z, Zhou L, Hu K, Dai Y, et al
    Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Mar 7. pii: 10.1038/s41409-018-0146.
    PubMed     Text format     Abstract available


    February 2018
  78. OCHI K, Fuji S, Takano K, Tajima K, et al
    The putative anti-leukemic effects of anti-thymocyte globulins in patients with CD7-positive acute myeloid leukemia.
    Bone Marrow Transplant. 2018 Feb 19. pii: 10.1038/s41409-018-0115.
    PubMed     Text format     Abstract available


  79. BHATT VR, Chen B, Lee SJ
    Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study.
    Bone Marrow Transplant. 2018 Feb 5. pii: 10.1038/s41409-018-0105.
    PubMed     Text format     Abstract available


  80. ZHANG Q, Zhou Y, Majaw JK, Xu J, et al
    Acute appendicitis in leukaemia patients undergoing haematopoietic stem cell transplantation during the neutropaenic phase: a case series from a single BMT centre in China.
    Bone Marrow Transplant. 2018;53:219-222.
    PubMed     Text format    


  81. RASHIDI A, Linden MA, Percival ME, Sandmaier BM, et al
    Recommendations for reporting post-transplant relapse in AML.
    Bone Marrow Transplant. 2018;53:111-113.
    PubMed     Text format    


    January 2018
  82. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-017-0082.
    PubMed     Text format    


  83. ALHASHIM N, Aljurf M, Hassanein M, Chaudhri N, et al
    Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-018-0093.
    PubMed     Text format     Abstract available


  84. LAHOUD OB, Moskowitz AJ, Horwitz SM, Giralt SA, et al
    Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Jan 22. pii: 10.1038/s41409-017-0086.
    PubMed     Text format    


  85. AMRO ELSHOURY, Wallace PK, Borowitz MJ, Kader A, et al
    BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Jan 17. pii: 10.1038/s41409-017-0036.
    PubMed     Text format    


  86. CESARO S, Crocchiolo R, Tridello G, Knelange N, et al
    Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0016.
    PubMed     Text format     Abstract available


  87. OGAWA H, Ikegame K, Daimon T, Uchida N, et al
    Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0028.
    PubMed     Text format    


  88. JIANG Z, Jia J, Yue C, Pang Y, et al
    Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0049.
    PubMed     Text format     Abstract available


  89. DEVILLIER R, Labopin M, Chevallier P, Ledoux MP, et al
    Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Ma
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0043.
    PubMed     Text format     Abstract available


  90. WAIS V, Kundgen L, Bohl SR, von Harsdorf S, et al
    Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Bone Marrow Transplant. 2018;53:94-96.
    PubMed     Text format    


    December 2017
  91. MILONE G, Sacchi N, Gallina A, Leotta S, et al
    Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0026.
    PubMed     Text format     Abstract available


  92. GADALLA SM, Wang T, Loftus D, Friedman L, et al
    No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0029.
    PubMed     Text format     Abstract available


  93. KETTERL TG, Wu D, Fromm JR, Soma L, et al
    Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0037.
    PubMed     Text format    


  94. VAN GORKOM G, van Gelder M, Eikema DJ, Blok HJ, et al
    Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
    Bone Marrow Transplant. 2017 Dec 18. pii: 10.1038/s41409-017-0023.
    PubMed     Text format     Abstract available


    October 2017
  95. CHO C, Hsu M, Barba P, Maloy MA, et al
    Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  96. HEMMATI PG, Pfeifer K, Vuong LG, Jehn CF, et al
    Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    September 2017
  97. SCHEID C, de Wreede L, van Biezen A, Koenecke C, et al
    Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2017 Sep 11. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  98. KORDELAS L, Buttkereit U, Lindemann M, Koldehoff M, et al
    alphabeta-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  99. MODI D, Deol A, Kim S, Ayash L, et al
    Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    August 2017
  100. FREEMAN AT, Stover AM, Grover NS, Shea TC, et al
    Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  101. LAHTEENMAKI K, Wacklin P, Taskinen M, Tuovinen E, et al
    Haematopoietic stem cell transplantation induces severe dysbiosis in intestinal microbiota of paediatric ALL patients.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    July 2017
  102. GEETHAKUMARI PR, Leiby B, Nair R, Alpdogan SO, et al
    Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Jul 31. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  103. FERGUSON P, Craddock C
    Allogeneic transplantation in primary refractory AML.
    Bone Marrow Transplant. 2017;52:950-951.
    PubMed     Text format    


    June 2017
  104. NGUYEN S, Achour A, Souchet L, Vigouroux S, et al
    Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Societe Francaise de Gref
    Bone Marrow Transplant. 2017 Jun 26. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  105. TERAKURA S, Kuwatsuka Y, Yamasaki S, Wake A, et al
    GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.
    Bone Marrow Transplant. 2017 Jun 12. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  106. ZHANG R, Shi W, Wang HF, You Y, et al
    Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  107. LITZOW MR, Fielding AK, Luger SM, Paietta E, et al
    The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  108. GROS FX, Cazaubiel T, Forcade E, Lechevalier N, et al
    Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  109. SALEM R, Massoud R, Haffar B, Mahfouz R, et al
    Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  110. VAN DE PEPPEL RJ, von dem Borne PA, le Cessie S, de Boer MGJ, et al
    A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS.
    Bone Marrow Transplant. 2017;52:883-888.
    PubMed     Text format     Abstract available


    May 2017
  111. JETHAVA YS, Sica S, Savani B, Socola F, et al
    Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.
    Bone Marrow Transplant. 2017 May 15. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    April 2017
  112. YU J, Hu Y, Pu C, Liang Z, et al
    Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.
    Bone Marrow Transplant. 2017 Apr 24. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  113. SIMONIN M, Dalissier A, Labopin M, Willasch A, et al
    More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Workin
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  114. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  115. GARNIER A, Guillaume T, Peterlin P, Bene MC, et al
    Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  116. BILL M, Jentzsch M, Grimm J, Schubert K, et al
    Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  117. SELLNER L, Bruggemann M, Schlitt M, Knecht H, et al
    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Bone Marrow Transplant. 2017;52:656.
    PubMed     Text format    


  118. SCHETELIG J, de Wreede LC, van Gelder M, Andersen NS, et al
    Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2017;52:552-560.
    PubMed     Text format     Abstract available


  119. ANDERSSON BS, Thall PF, Valdez BC, Milton DR, et al
    Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.
    Bone Marrow Transplant. 2017;52:580-587.
    PubMed     Text format     Abstract available


    March 2017
  120. TERAKURA S, Wake A, Inamoto Y, Murata M, et al
    Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
    Bone Marrow Transplant. 2017;52:423-430.
    PubMed     Text format     Abstract available


  121. VAN GELDER M, de Wreede LC, Bornhauser M, Niederwieser D, et al
    Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2017;52:372-380.
    PubMed     Text format     Abstract available


  122. ANTAR A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, et al
    Inhibition of FLT3 in AML: a focus on sorafenib.
    Bone Marrow Transplant. 2017;52:344-351.
    PubMed     Text format     Abstract available


    February 2017
  123. BLUM V, Heini AD, Novak U, Taleghani BM, et al
    Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML.
    Bone Marrow Transplant. 2017 Feb 13. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  124. YAMASHITA T, Ikegame K, Kojima H, Tanaka H, et al
    Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Feb 6. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  125. EDER S, Labopin M, Finke J, Bunjes D, et al
    Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
    Bone Marrow Transplant. 2017;52:238-244.
    PubMed     Text format     Abstract available


    January 2017
  126. DULERY R, Nibourel O, Gauthier J, Elsermans V, et al
    Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  127. CARRE M, Thiebaut-Bertrand A, Larrat S, Leroy V, et al
    Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  128. KHOURI IF, Sui D, Jabbour EJ, Samuels BI, et al
    Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
    Bone Marrow Transplant. 2017;52:28-33.
    PubMed     Text format     Abstract available


  129. ZHENG CC, Zhu XY, Tang BL, Zhang XH, et al
    Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Bone Marrow Transplant. 2017;52:88-94.
    PubMed     Text format     Abstract available


    December 2016
  130. LEGRAND F, Le Floch AC, Granata A, Furst S, et al
    Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    November 2016
  131. ALBRING JC, Inselmann S, Sauer T, Schliemann C, et al
    PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    September 2016
  132. SARACENI F, Bruno B, Lemoli RM, Meloni G, et al
    Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.
    Bone Marrow Transplant. 2016 Sep 26. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  133. WILLASCH AM, Salzmann-Manrique E, Krenn T, Duerken M, et al
    Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  134. GATTI-MAYS ME, Manion M, Bowen LN, Brown GT, et al
    Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  135. PHILLIPS EH, Hodson A, Hermine O, Bazarbachi A, et al
    Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    August 2016
  136. O'DONNELL PV, Eapen M, Horowitz MM, Logan BR, et al
    Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.
    Bone Marrow Transplant. 2016 Aug 15. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    July 2016
  137. MAGENAU J, Westervelt P, Khaled S, McGuirk J, et al
    A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  138. EHRLICH KB, Miller GE, Scheide T, Baveja S, et al
    Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    June 2016
  139. TSIRIGOTIS P, Byrne M, Schmid C, Baron F, et al
    Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  140. POHLEN M, Groth C, Sauer T, Gorlich D, et al
    Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years).
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    May 2016
  141. KRUGER P, Cooney J, Nivison-Smith I, Dodds A, et al
    All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.
    Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  142. LAM W, Viswabandya A, Hussain S, Messner HA, et al
    A unique case of tuberculosis dissemination presenting as cutaneous lesions in a post allogeneic stem cell transplant patient.
    Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  143. RASHIDI A, DiPersio JF, Westervelt P, Abboud CN, et al
    HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    April 2016
  144. RAMANATHAN M, Teira P, Battiwalla M, Barrett J, et al
    Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: